HONG KONG, March 20, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) presented promising phase III safety run-in results from the COMPASSION-18/AK104-305 study, at the 2025 Annual Meeting of the Society of Gynecologic Oncology (SGO). The study evaluates the global first-in-class PD-1/CTLA-4...
Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso's Cadonilimab Combined with Concurrent Chemoradiotherapy Demonstrates Promising Efficacy in Locally Advanced Cervical Cancer: Data Published at the 2025 SGO Annual Meeting )
Also on site :
- (Video) Person stabbed after two cut line for Pokémon cards in Bay Area: PD
- US fighter jet intercepts suspicious plane over Trump’s golf club
- A four-year-old died after a drive-by shooting at a Detroit playground. Now two teens have been charged.